Want to see KR:063160 full AI Analyst Report?
Top Page
CKD Bio Corp.
(063160)
Select Model
Select Model
Rating:42Neutral
Price Target:
$11,616.00
Action:N/A
Date:10/28/26
The score is held down primarily by weakening financial performance—recent losses, contracting revenue, and negative free cash flow are the biggest risks. Technical indicators also remain broadly bearish with the stock trading below key moving averages and negative MACD, though oversold readings may offer limited near-term support. Valuation is difficult to assess due to the negative P/E and lack of dividend yield data.
Positive Factors
Integrated drug platform
CKD Bio combines drug development, manufacturing, and marketing within one operating platform. This integration can support control over product supply and commercialization while allowing the company to retain capabilities across the value chain as it develops and sells specialty and chronic-disease medicines.
Negative Factors
Contracting revenue
Recent revenue contraction signals weaker demand, product performance, or commercial execution than in 2024. If the decline persists, it can reduce operating leverage, limit reinvestment capacity, and make it harder for CKD Bio to recover margins while funding pharmaceutical development.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated drug platform
CKD Bio combines drug development, manufacturing, and marketing within one operating platform. This integration can support control over product supply and commercialization while allowing the company to retain capabilities across the value chain as it develops and sells specialty and chronic-disease medicines.
Read all positive factors
CKD Bio Corp. (063160) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩67.64B
Dividend Yield0.46%
Average Volume (3M)29.26K
Price to Earnings (P/E)―
Beta (1Y)0.18
Revenue Growth2.72%
EPS Growth-3186.88%
CountryKR
Employees533
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,485,962
10 Day Avg. Volume7,993
30 Day Avg. Volume29,256
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.88
Price to Sales (P/S)0.70
P/FCF Ratio-10.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CKD Bio Corp. Business Overview & Revenue Model
Company Description
CKD Bio Corp., a South Korean company founded in 1941 and headquartered in Seoul, specializes in the production and distribution of pharmaceutical active ingredients (APIs). Their manufacturing processes leverage diverse technologies, including fe...
CKD Bio Corp. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
46
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.12B | 160.07B | 171.76B | 160.35B | 156.04B | 142.24B |
| Gross Profit | 13.61B | 26.10B | 35.94B | 5.01B | 16.79B | 13.31B |
| EBITDA | 8.54B | 19.26B | 31.17B | -1.63B | 2.29B | 5.56B |
| Net Income | -10.74B | -2.89B | 8.70B | -24.19B | -16.70B | -6.58B |
Balance Sheet | ||||||
| Total Assets | 293.05B | 299.87B | 284.49B | 293.79B | 312.59B | 298.54B |
| Cash, Cash Equivalents and Short-Term Investments | 587.63M | 1.50B | 1.16B | 3.70B | 12.72B | 3.53B |
| Total Debt | 147.94B | 144.96B | 131.21B | 146.93B | 138.93B | 109.38B |
| Total Liabilities | 173.48B | 172.83B | 153.48B | 170.76B | 164.79B | 137.05B |
| Stockholders Equity | 119.57B | 127.04B | 131.01B | 123.02B | 147.80B | 161.49B |
Cash Flow | ||||||
| Free Cash Flow | -9.74B | -10.95B | 9.75B | -18.00B | -10.43B | -26.59B |
| Operating Cash Flow | 1.01B | -4.14B | 14.03B | -7.22B | -3.20B | -5.88B |
| Investing Cash Flow | -10.91B | -6.96B | -4.75B | -1.20B | -20.55B | -20.39B |
| Financing Cash Flow | 9.01B | 11.45B | -11.81B | 7.40B | 24.96B | 28.27B |
CKD Bio Corp. Technical Analysis
Negative
―
Price Trends
13275.40
Negative
13568.50
Negative
16583.35
Negative
Market Momentum
-277.06
Positive
40.63
Neutral
23.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:063160, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 13041.00, equal to the 50-day MA of 13275.40, and equal to the 200-day MA of 16583.35, indicating a bearish trend. The MACD of -277.06 indicates Positive momentum. The RSI at 40.63 is Neutral, neither overbought nor oversold. The STOCH value of 23.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:063160.
CKD Bio Corp. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₩1.16T | 5.95 | ― | 0.59% | 9.87% | 160.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₩1.59T | 130.86 | ― | 0.42% | 13.88% | 29.24% | |
49 Neutral | ₩76.86B | -8.16 | ― | ― | -5.10% | 19.68% | |
46 Neutral | ₩322.72B | -55.36 | ― | 2.07% | 15.38% | ― | |
42 Neutral | ₩67.64B | -6.30 | ― | 0.46% | 2.72% | -3186.88% | |
40 Underperform | ₩40.05B | -0.23 | ― | ― | 26.13% | 58.75% |
* General Sector Average
KR:063160
CKD Bio Corp.
12,330.00
-9,270.00
-42.92%
KR:003060
Aprogen Biologics
1,335.00
-6,945.00
-83.88%
KR:068760
Celltrion Pharm Inc.
36,650.00
-25,696.91
-41.22%
KR:069620
Daewoong Pharmaceutical Co., Ltd.
101,100.00
-37,819.86
-27.22%
KR:170900
Dong-A ST Co., Ltd.
33,850.00
-12,035.84
-26.23%
KR:183490
Enzychem Lifesciences Corp.
990.00
-27.00
-2.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.